Title of article
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial
Author/Authors
M Bocchia، نويسنده , , S Gentili، نويسنده , , R. V. Abruzzese، نويسنده , , A Fanelli، نويسنده , , F Iuliano، نويسنده , , A Tabilio، نويسنده , , M Amabile، نويسنده , , F Forconi، نويسنده , , Giuseppe Gozzetti، نويسنده , , D Raspadori، نويسنده , , S Amadori، نويسنده , , F Lauria، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2005
Pages
6
From page
657
To page
662
Abstract
Background
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach complete cytogenetic remission (CCR) and most maintain detectable disease at the molecular level. We investigated whether a vaccine targeting the
Journal title
The Lancet
Serial Year
2005
Journal title
The Lancet
Record number
587708
Link To Document